Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, June 24 at 2:00 PM EDT

Register Free →

This Government Contract opportunity from Department Of Defense was posted on May 15, 2026. The submission period has ended. Browse the details below for market research, or find similar active opportunities.

Notice of Intent to Sole Source Mouse Brain Neurohistology

Closed
USU_NoticeOfIntent_Mouse_Brain_NeurohistologyFederal

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

Active Opportunities Like This One

NAICS: 541714
New
Grant
HEAL Initiative: Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] to Treat Pain (UG3/UH3 Clinical Trial Optional)This contract opportunity from the National Institutes of Health under the Department of Health and Human Services aims to support the development of safe, effective, and non-addictive small molecule and biologic therapeutics for pain treatment. It focuses on accelerating early-stage therapeutic candidates through preclinical optimization to readiness for Phase II clinical trials. Eligible applicants must present a promising lead candidate with strong biological justification and established assays to guide optimization. The funded activities include lead optimization, early development, IND-enabling studies, biomarker development, submission of an Investigational New Drug application, and Phase I clinical testing. The program is structured as a milestone-driven, phased cooperative agreement with active NIH involvement in project planning and monitoring. The solicitation is identified as RFA-NS-27-007, titled HEAL Initiative: Non-addictive Analgesic Therapeutics Development, with clinical trials optional. The solicitation was posted on June 16, 2026, and applicants must respond by February 20, 2029. This federal contract emphasizes collaborative advancement of innovative pain therapeutics while ensuring rigorous oversight from NIH program staff throughout the project lifecycle.
National Institutes Of Health

POSTED

about 21 hours ago

DEADLINE

in over 2 years
NAICS: 541714
New
Federal
TECHNOLOGY LICENSING OPPORTUNITY: DC RecruiterDC Recruiter is an innovative immune-enhancing technology developed by scientists at Los Alamos National Laboratory that uses a self-assembling peptide nanofiber to recruit and activate dendritic cells, critical components of the immune system. Unlike traditional pathogen-specific vaccines and treatments, this approach is designed to trigger an early, broad-spectrum immune response regardless of the specific infectious agent. The product is formulated as a needle-free, spray-friendly application, enhancing its practicality and ease of use in various settings. Its core advantage lies in addressing the challenge of rapid immune activation before the pathogen is identified, providing fast-acting defense during exposure scenarios where conventional methods may be delayed, too specific, or ineffective. This technology holds promise across multiple market sectors, including infectious disease prevention, outbreak management, national defense, consumer health, pharmaceuticals, and emergency preparedness. Its broad, pathogen-agnostic mechanism makes it especially valuable in high-risk or field environments requiring quick deployment and flexible administration. Currently at a technology readiness level of 3, DC Recruitor is patent-pending and available for licensing through Los Alamos National Laboratory’s program, which facilitates exclusive and non-exclusive licensing agreements to commercial partners seeking to leverage cutting-edge innovations for competitive advantage. The ongoing solicitation invites potential collaborators to engage before the stated deadline.
Triad - DOE Contractor

POSTED

2 days ago

DEADLINE

in 6 months
NAICS: 541714
New
Federal
Contact Activation Pathway Function Blocking Antibody AB023The Defense Health Agency is conducting a Request for Information (RFI) to gather market intelligence and identify qualified sources for the supply of the contact activation pathway function blocking antibody AB023, also known as Xisomab 3G3 or Gruticibart. This antibody is designed to inhibit Coagulation Factor XI (FXI) by targeting the "apple 2" domain, preventing its activation by activated factor XII (FXIIa) in the contact pathway, which is implicated in clot formation on artificial surfaces. The antibody is intended for use in medical applications such as Extracorporeal Membrane Oxygenation (ECMO) circuits, hemodialysis, catheters, and cancer-associated thrombosis. It is designed to preserve natural clotting processes by not interfering with FXI activation by thrombin or the conversion of Factor IX by activated FXI, thus maintaining normal hemostasis required for wound healing. The Government anticipates procuring up to 0.5 grams of AB023 annually and requires pharmacokinetic and pharmacodynamic testing to assess its concentration over time, biochemical impacts, clotting time effects, and ability to prevent thrombus growth and fibrin accumulation in vascular thrombosis models. Stability, dosage, and potency validations must be conducted using clotting assays. Although this announcement does not represent a solicitation or obligation to award a contract, interested parties with relevant expertise must submit technical information by June 18, 2026. All responders must be registered in the System for Award Management (SAM). The associated NAICS code is 541714, reflecting research and development in biotechnology. The point of contact is based at the Defense Health Agency in Fort Detrick, Maryland, with the place of performance listed in Texas.
Defense Health Agency

POSTED

5 days ago

DEADLINE

in 1 day

AI Contract Overview

Show more

The Department of Defense, through the Uniformed Services University of the Health Sciences (USUHS), plans to award a sole-source, firm-fixed-price contract to NeuroScience Associates Inc. for specialized neurohistology services focusing on mouse brain hemispheres. This contract is aligned with NAICS code 541714, which pertains to specialized scientific and technical consulting services. The work will be performed in Bethesda, Maryland, and the intent is to secure these critical research services without competitive bidding, underscoring the specialized nature or unique capabilities of the selected vendor. The contract notice was posted on May 15, 2026, with a response deadline set for May 30, 2026. The liaison for this procurement is Shea Foster, who can be contacted via email for any inquiries. This action reflects USUHS’s need to advance neurohistological research capabilities critical to its mission, leveraging the demonstrated expertise of NeuroScience Associates Inc. The publicly accessible notice provides transparency in the sole-source procurement process while clearly outlining the scope and location of the required services.

General Info

USUHS awards sole-source contract to NeuroScience Associates for specialized mouse brain neurohistology services in Bethesda.

Agency

Department Of Defense → Usuhs

NAICS

541714 - Research and Development in Biotechnology (except Nanobiotechnology)View NAICS

Place of Performance

Bethesda, MD, 20814, USA

Set-Aside

NONE

Documents

(1)

Notice of Intent to Sole Source for Mouse Brain Neurohistology

PDFnotice-of-intent

AI Contract Breakdown

Uniform Contract Format

Sign up to view the full breakdown with detailed analysis of each section.

Timeline

PhaseClosed
Posted

special-notice

Response Deadline

Deadline has passed

Submission Closed

Find active opportunities like this

Start your free trial to discover similar active contracts, track opportunities, and build proposals with AI assistance.

Organization & Contact Information

Show more
AgencyDepartment Of Defense → Usuhs
Contacts1 person available
OfficeBETHESDA, MD, 20814-4712, USA
Organization / Agency
Department Of Defense → Usuhs
Office AddressBETHESDA, MD, 20814-4712, USA
Contacts

Full Description

Show more

USU intends to award a sole-source, firm-fixed-price contract to NeuroScience Associates Inc. for mouse brain hemispheres nuerohistology. See attached notice for details.